Natera, Inc.
NTRA
Classement en actions
#413
Natera, Inc. is a diagnostics company focused on developing and commercializing... Natera, Inc. is a diagnostics company focused on developing and commercializing a wide array of molecular testing services globally. Its portfolio includes several key offerings: Panorama, a non-invasive prenatal test (NIPT) that screens for chromosomal abnormalities in a fetus using a blood sample from the mother, and also determines zygosity in twin pregnancies. Vistara, designed to identify single-gene disorders by screening for specific single-gene mutations. Horizon, a comprehensive carrier screening test to determine an individual's carrier status for various genetic diseases. Spectrum, utilized during in vitro fertilization (IVF) cycles to detect chromosomal anomalies or inherited genetic conditions. Anora, a miscarriage analysis product that examines fetal chromosomes to help understand the cause of pregnancy loss. Non-invasive paternity testing, which establishes paternity during gestation using blood samples from both the pregnant mother and the alleged father. Beyond reproductive health, Natera also provides specialized tests: Signatera, a sophisticated circulating tumor DNA (ctDNA) technology capable of screening for a generic set of mutations, independent of the individual's specific tumor characteristics. Prospera, a test used to assess and monitor organ transplant rejection. Additionally, the company offers Constellation, a cloud-based software platform that provides laboratory clients with access to Natera's proprietary algorithms and bioinformatics, enabling them to validate and launch their own tests. Natera distributes its products through a direct sales team and an extensive network of approximately 100 laboratory and distribution partners. The company has strategic partnerships, including one with BGI Genomics Co., Ltd. for the development, manufacturing, and commercialization of NGS-based genetic testing assays, and another with Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. Founded in 2003, Natera, Inc. is headquartered in Austin, Texas. It was formerly known as Gene Security Network, Inc. before changing its name in 2012.
Prix de l'action
$403.81
Capitalisation boursière
$58.21B
Changement (1 jour)
2.63%
Changement (1 an)
122.25%
Pays
US
Échange Natera, Inc. (NTRA)
Catégorie
Healthcare
Marge opérationnelle de Natera, Inc. (NTRA)
Marge opérationnelle au October 2026 TTM : -10.70%
Selon les derniers rapports financiers et le cours de l'action de Natera, Inc., la marge opérationnelle actuelle (TTM) est de -10.70%. À la fin de 2023, elle était de -41.22%.
Historique de la marge opérationnelle pour Natera, Inc. de 2012 à 2026
Marge opérationnelle à la fin de chaque année
| Année | Marge opérationnelle | Changez |
|---|---|---|
| 2026 (TTM) | -10.70% | -18.32% |
| 2024 | -13.10% | -68.22% |
| 2023 | -41.22% | -37.51% |
| 2022 | -65.96% | -11.88% |
| 2021 | -74.85% | 35.33% |
| 2020 | -55.31% | 43.81% |
| 2019 | -38.46% | -13.55% |
| 2018 | -44.49% | -29.98% |
| 2017 | -63.54% | 42.95% |
| 2016 | -44.45% | 41.43% |
| 2015 | -31.43% | -7,583.33% |
| 2014 | 0.42% | -100.92% |
| 2013 | -45.80% | -66.03% |
| 2012 | -134.84% | 0.00% |
Marge opérationnelle pour des entreprises similaires ou concurrentes
| Entreprise | Marge opérationnelle | Différence de Marge Opérationnelle | Pays |
|---|---|---|---|
| 17.97% | -101.68% |
US
|
|
| 20.42% | -101.91% |
US
|
|
| 0.00% | - |
CN
|
|
| 22.23% | -102.08% |
US
|
|
| 32.03% | -102.99% |
US
|
Qu'est-ce que la Marge opérationnelle d'une entreprise ?
La Marge opérationnelle est un indicateur clé pour évaluer la rentabilité d'une entreprise. Une marge d'exploitation plus élevée est généralement préférable car elle montre qu'une entreprise peut vendre ses produits ou services bien au-dessus de leurs coûts de production. Elle se calcule en divisant les bénéfices par le chiffre d'affaires.